HomeAI · summaries
Storia in 3 fonti
Dr Reddy's Q1 profit falls 69% to ₹434 crore as lenalidomide transition weighs
Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Q1 FY27 preview: Dr Reddy’s likely to face pressure on earnings
Dr Reddy's FY27 Q1 preview indicates potential earnings pressure, with analysts predicting significant declines in profit and EBITDA.
- ·
Dr Reddy's Q1 profit falls 69% to ₹434 crore as lenalidomide transition weighs
Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.
